You are here

Cognition Therapeutics Receives European Patent Covering its Alzheimer's Disease Candidate, Elayta™

Pittsburgh, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders, today announced the issuance by the European Patent Office of a composition of matter patent covering Elayta™, Cognition’s lead clinical stage compound in development for individuals with Alzheimer's disease.
Thursday, February 21, 2019 - 08:03